101 Startups
  • Sector
  • Participated in
  • Year of participation

Scope Biosciences

  • 2020
  • Diagnostics
  • Venture Challenge
CRISPR-Cas has revolutionized the field of gene editing and will also disrupt the field of molecular diagnostics. CRISPR diagnostics (CRISPR-Dx), combined with a pre-amplification step, are faster and easier than (q)PCR whilst obtaining results of the same quality.

Self-Screen

  • 2010
  • Diagnostics
  • Other
Development and clinical application of molecular assays for the early detection of cancer

Sella Therapies

  • 2021
  • Medical Device
  • Therapeutics
  • Venture Challenge
Sella Therapies is a clinical-stage medical device company developing a novel therapy for chronic pain relief that targets the body’s internal neuropeptide system.

SeraNovo

  • 2018
  • Enabling Technology
  • Venture Challenge
SeraNovo’s proprietary formulation platform radically increases bioavailability and allows products to reach the market significantly quicker, at a lower cost.

ShanX Medtech

  • 2020
  • Diagnostics
  • Venture Challenge
Providing a reliable UTI diagnosis and simultaneously indicating the optimal antibiotic prescription in under 4 hours

Sirius Medical

  • 2015
  • Medical Device
  • Venture Challenge
The next generation of accurate and hassle-free tumor localization for breast cancer.

SLAM Orthopedic

  • 2020
  • Medical Device
  • Venture Challenge
SLAM Ortho has developed an automated, accurate and fast bore depth measurement system for use in orthopaedic trauma procedures for fractures in extremities

STENTiT

  • 2016
  • Medical Device
  • Venture Challenge
To become the new standard in vascular treatment. By bringing regenerative capacity for the first time to a stent, a wide range of clinical applications will benefit from our innovative approach.

T-Cell Factory

  • 2013
  • Enabling Technology
  • Therapeutics
  • Venture Challenge
T Cell Factory (TCF) will identify and develop therapeutic T cell receptor (TCR) genes for the growing market of cancer therapies.

TargED Biopharmaceuticals

  • 2018
  • Therapeutics
  • Venture Challenge
We at TargED have developed MICROLYSE, an innovative fusion-protein that has an antibody domain that recognizes microthrombi and an enzymatic domain that breaks them down.